
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
أحدث البيانات المتاحة
1.23 US$
0.00 US$ · 0.00%
Sonoma Pharmaceuticals, Inc. specializes in the creation and distribution of stabilized hypochlorous acid (HOCl) products. These offerings address a diverse range of medical and health needs, including wound management, veterinary care, ocular hygiene, oral health, and various dermatological conditions. The company's market reach extends across the United States, Latin America, Europe, and other international territories. Its comprehensive product line features: Epicyn: an antimicrobial cleanser for facial use. Levicyn: a prescription HOCl-based treatment formulated to ease the burning, itching, and pain associated with numerous dermatological issues. Celacyn gel: a topical HOCl-based prescription product engineered to facilitate efficient healing and management of both new and old scars. SebuDerm: designed to soothe the burning, itching, redness, scaling, and discomfort linked to seborrhea and seborrheic dermatitis. Acuicyn: an HOCl-based solution for alleviating ocular itch and inflammation, while also maintaining cleanliness around the eyes. Microcyn: a topical HOCl product family aimed at accelerating wound healing by combating a wide spectrum of pathogens, including antibiotic-resistant strains that can impede natural recovery. MicrocynAH: an HOCl-based solution specifically for animals, providing relief for common conditions like hot spots, scratches, skin rashes, post-surgical sites, and irritated skin to support healing. Microdacyn60: an oral care solution for treating infections of the mouth and throat. MucoClyns: suitable for emergency use and safe for application on mucous membranes, cuts, abrasions, burns, and other body surfaces. Endocyn: a series of solutions for root canal irrigation. Pediacyn: a hydrogel designed for atopic dermatitis. Ocucyn: a cleanser for eyelids and eyelashes. Gramaderm: for the topical treatment of mild to moderate acne. Nanocyn: a hospital-grade disinfectant. Sinudox: for nasal irrigation purposes. Originally incorporated in 1999 as Oculus Innovative Sciences, Inc., the company officially rebranded to Sonoma Pharmaceuticals, Inc. in December 2016. Its headquarters are located in Woodstock, Georgia.
الإغلاق السابق
1.23 US$
0.00 US$ · 0.00%
بعد ساعات التداول
1.23 US$
0.00 US$ · 0.00%
12 أكتوبر، 7:11 م ET
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
Sonoma Pharmaceuticals, Inc. specializes in the creation and distribution of stabilized hypochlorous acid (HOCl) products. These offerings address a diverse range of medical and health needs, including wound management, veterinary care, ocular hygiene, oral health, and various dermatological conditions. The company's market reach extends across the United States, Latin America, Europe, and other international territories. Its comprehensive product line features: Epicyn: an antimicrobial cleanser for facial use. Levicyn: a prescription HOCl-based treatment formulated to ease the burning, itching, and pain associated with numerous dermatological issues. Celacyn gel: a topical HOCl-based prescription product engineered to facilitate efficient healing and management of both new and old scars. SebuDerm: designed to soothe the burning, itching, redness, scaling, and discomfort linked to seborrhea and seborrheic dermatitis. Acuicyn: an HOCl-based solution for alleviating ocular itch and inflammation, while also maintaining cleanliness around the eyes. Microcyn: a topical HOCl product family aimed at accelerating wound healing by combating a wide spectrum of pathogens, including antibiotic-resistant strains that can impede natural recovery. MicrocynAH: an HOCl-based solution specifically for animals, providing relief for common conditions like hot spots, scratches, skin rashes, post-surgical sites, and irritated skin to support healing. Microdacyn60: an oral care solution for treating infections of the mouth and throat. MucoClyns: suitable for emergency use and safe for application on mucous membranes, cuts, abrasions, burns, and other body surfaces. Endocyn: a series of solutions for root canal irrigation. Pediacyn: a hydrogel designed for atopic dermatitis. Ocucyn: a cleanser for eyelids and eyelashes. Gramaderm: for the topical treatment of mild to moderate acne. Nanocyn: a hospital-grade disinfectant. Sinudox: for nasal irrigation purposes. Originally incorporated in 1999 as Oculus Innovative Sciences, Inc., the company officially rebranded to Sonoma Pharmaceuticals, Inc. in December 2016. Its headquarters are located in Woodstock, Georgia.
نطاق اليوم
السعر الحالي 1.23 US$
نطاق 52 أسبوعًا
السعر الحالي 1.23 US$
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
نقاط GoAI
احتفاظ
تقييم
69
أقل من القيمة
المشاعر
53
مختلط
المخاطر
69
مخاطر مرتفعة
الزخم
31
زخم متراجع
بحث كامل عن GoAI
تابع للاطلاع على أدلة ومحفزات ومخاطر أعمق.
Sonoma Pharmaceuticals, Inc. specializes in the creation and distribution of stabilized hypochlorous acid (HOCl) products. These offerings address a diverse range of medical and health needs, including wound management, veterinary care, ocular hygiene, oral health, and various dermatological conditions. The company's market reach extends across the United States, Latin America, Europe, and other international territories. Its comprehensive product line features: Epicyn: an antimicrobial cleanser for facial use. Levicyn: a prescription HOCl-based treatment formulated to ease the burning, itching, and pain associated with numerous dermatological issues. Celacyn gel: a topical HOCl-based prescription product engineered to facilitate efficient healing and management of both new and old scars. SebuDerm: designed to soothe the burning, itching, redness, scaling, and discomfort linked to seborrhea and seborrheic dermatitis. Acuicyn: an HOCl-based solution for alleviating ocular itch and inflammation, while also maintaining cleanliness around the eyes. Microcyn: a topical HOCl product family aimed at accelerating wound healing by combating a wide spectrum of pathogens, including antibiotic-resistant strains that can impede natural recovery. MicrocynAH: an HOCl-based solution specifically for animals, providing relief for common conditions like hot spots, scratches, skin rashes, post-surgical sites, and irritated skin to support healing. Microdacyn60: an oral care solution for treating infections of the mouth and throat. MucoClyns: suitable for emergency use and safe for application on mucous membranes, cuts, abrasions, burns, and other body surfaces. Endocyn: a series of solutions for root canal irrigation. Pediacyn: a hydrogel designed for atopic dermatitis. Ocucyn: a cleanser for eyelids and eyelashes. Gramaderm: for the topical treatment of mild to moderate acne. Nanocyn: a hospital-grade disinfectant. Sinudox: for nasal irrigation purposes. Originally incorporated in 1999 as Oculus Innovative Sciences, Inc., the company officially rebranded to Sonoma Pharmaceuticals, Inc. in December 2016. Its headquarters are located in Woodstock, Georgia.
نطاق اليوم
السعر الحالي 1.23 US$
نطاق 52 أسبوعًا
السعر الحالي 1.23 US$
الربحية كنسبة مئوية من الإيرادات المعلنة.
الإيرادات
الدخل التشغيلي
صافي الدخل
| البند (USD) | السنة المالية 2026 | السنة المالية 2025 | السنة المالية 2024 | السنة المالية 2023 | السنة المالية 2022 |
|---|---|---|---|---|---|
| الإيرادات | 19.53 مليون USD | 14.29 مليون USD | 12.74 مليون USD | 13.27 مليون USD | 12.63 مليون USD |
| تكلفة البضاعة المباعة | 12.11 مليون USD | 8.82 مليون USD | 7.99 مليون USD | 8.8 مليون USD | 8.64 مليون USD |
| الربح الإجمالي | 7.42 مليون USD | 5.47 مليون USD | 4.75 مليون USD | 4.48 مليون USD | 3.99 مليون USD |
| البحث والتطوير | 2.27 مليون USD | 1.81 مليون USD | 1.87 مليون USD | 207 ألف USD | 125 ألف USD |
| مصاريف البيع والمصاريف العمومية والإدارية | 7.61 مليون USD | 7.36 مليون USD | 7.58 مليون USD | 8.84 مليون USD | 9.76 مليون USD |
| نفقات التشغيل | 9.88 مليون USD | 9.18 مليون USD | 9.45 مليون USD | 9.05 مليون USD | 9.88 مليون USD |
| دخل الفوائد | — | — | — | 16 ألف USD | — |
| مصاريف الفوائد | — | — | — | — | 10 ألف USD |
| الاستهلاك والإطفاء | 139 ألف USD | 138 ألف USD | 176 ألف USD | 125 ألف USD | 186 ألف USD |
| الدخل التشغيلي | −2.46 مليون USD | −3.71 مليون USD | −4.7 مليون USD | −4.57 مليون USD | −5.89 مليون USD |
| صافي الدخل | −3.18 مليون USD | −3.46 مليون USD | −4.84 مليون USD | −5.15 مليون USD | −5.09 مليون USD |
تم تحديث حقائق الشركة 13 أكتوبر 2026.
أحدث النتائج المعلنة
أحدث النتائج المعلنة
| الإجراء | تاريخ النفاذ | تفاصيل | تاريخ التسجيل | تاريخ الدفع |
|---|---|---|---|---|
تقسيم الأسهم | 30 أغسطس 2024 | 1:20 | — | — |
تقسيم الأسهم | 20 يونيو 2019 | 1:9 | — | — |
تقسيم الأسهم | 27 يونيو 2016 | 1:5 | — | — |
تقسيم الأسهم | 1 أبريل 2013 | 1:7 | — | — |
ساري 30 أغسطس 2024
1:20
ساري 20 يونيو 2019
1:9
ساري 27 يونيو 2016
1:5
ساري 1 أبريل 2013
1:7
المحتوى المُنشأ بالذكاء الاصطناعي وبيانات السوق المتأخرة لأغراض معلوماتية وتعليمية فقط، ولا تُعد نصيحة استثمارية.